Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

ELEVATE: Empowered social media coaching for oncologists.

Miriam Knoll, Emily Blotiau, Narjust Florez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21016

e21016 Background: Oncologists interested in building a social media presence often lack the training and tools to do so....

Immune checkpoint inhibition for advanced cutaneous squamous cell carcinoma in patients with concomitant chronic lymphocytic leukemia: Integrated single-center and national Cosmos analyses.

Luke M. Shenton, Jacob New, Natalia M. Orendain et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21565

e21565 Background: Patients with chronic lymphocytic leukemia (CLL) have immune dysregulation and increased risk of aggres...

Outcomes of inferior vena cava filters in breast cancer patients with DVT: National Inpatient Sample–based comparative analysis.

Oluchi Idenyi, Madhu Bhargavi Chandra, Veera Durga Vaishnavi Kurra et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12763

e12763 Background: Venous thromboembolism (VTE), including deep vein thrombosis (DVT), is a frequent complication of breas...

(RW) post-progression outcomes after first-line (1L) treatment with ribociclib + an aromatase inhibitor (AI) vs AI alone in US patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC).

Lowell L. Hart, Hope S. Rugo, VK Gadi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13044

e13044 Background: Ribociclib remains the only cyclin-dependent kinase 4/6 inhibitor to consistently demonstrate overall s...

Real-world clinical impact and prognostic utility of circulating tumor DNA in stage I–IV non–small cell lung cancer.

Fernando Poli, Andrea Poli de Frias, Eric Spinetti et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20091

e20091 Background: Circulating tumor DNA (ctDNA) is an established and widely used biomarker for detection of minimal resi...

Management of pancreatic metastases from renal cell carcinoma.

Vasiliki Michalaki, Maria Roxani Koutrouli, Konstantinos Iliakopoulos et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16526

e16526 Background: The pancreas is a rare site of metastases, although metastatic renal cell carcinoma (mRCC) is the most...

Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers.

Rohit Thummalapalli, Jierui Xu, Nuray Tezcan et al. Jun 01, 2026 pp. 4175-4175 10.1200/jco.2026.44.16_suppl.4175

4175 Background: Genomic loss of MTAP and CDKN2A...

The impact of online CME on addressing clinical decision-making for immunotherapy in advanced squamous NSCLC.

Michelle Arielle Worst, Andrew Small, Amy Furedy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21002

e21002 Background: Immunotherapy (IO)-based regimens are foundational to the management of advanced squamous non-small cel...

Real-world analysis of pneumonitis risk after chemoradiation and durvalumab by chemotherapy regimen in NSCLC.

Abida Babu, Jasmine Nadayil, Stephen Rosenberg et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20049

e20049 Background: Consolidation durvalumab after chemoradiation improves outcomes in patients with locally advanced NSCLC...

Distinct national mortality patterns in intrahepatic versus extrahepatic cholangiocarcinoma: A population-based study with future projections.

Sameer Ali, Maria Alejandra Molina Rodriguez, Ali Hassan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16255

e16255 Background: Cholangiocarcinoma (CCA) presents a rising global health concern. United States mortality patterns diff...

Preoperative combination radiotherapy (RT) and immune checkpoint inhibitor (ICI) in early-stage breast cancer: Influence of RT and ICI treatment sequencing (NCT04454528 post-hoc analysis).

Julia C. Tchou, Anupma Nayak, He N. Xu et al. Jun 01, 2026 pp. 615-615 10.1200/jco.2026.44.16_suppl.615

615 Background: The anti-tumor immune effects of combination radiotherapy (RT) and immune checkpoint inhibitors (ICI) are...

Generalizable cancer detection from ultra-low-pass whole-genome sequencing of cell-free DNA using a sequentially fine-tuned transformer framework.

Rui Liu, Yang Xu, Song Wang et al. Jun 01, 2026 pp. 10533-10533 10.1200/jco.2026.44.16_suppl.10533

10533 Background: Ultra-low-pass whole-genome sequencing (ULP-WGS) of cell-free DNA (cfDNA) provides a cost-effective appr...

Age-dependent survival gradients and projected future disease burden in adult acute lymphocytic leukemia: A population-based SEER analysis.

Sameer Krishna Prasad Garlapati, Madho Mal, Nayanika Chowdary Tummala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18542

e18542 Background: Outcomes in adult acute lymphocytic leukemia (ALL) remain heterogeneous and strongly influenced by age....

Enhancing diverse participation in cancer clinical trials: Evaluating theory-based recruitment messaging and visual imagery preferences among underrepresented adults.

Trevor Kauer, Elizabeth Flood-Grady, Courtny Franco et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24122

e24122 Background: Using multiple channels and theory-based recruitment messaging are strategies to enroll diverse audienc...

Single-agent versus combination paradigms: A systematic review and meta-analysis of the immunotherapy clinical profile in metastatic renal cell carcinoma.

Faseeh Haider, Muhammad Asjid, Eesha Zainab et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16549

e16549 Background: Immunotherapy-based combinations are established as the first-line standard of care for metastatic rena...

Lymphoma epidemiology in Syria: A 2024 analysis from the nation's primary oncology referral center.

Moudar Bakkour, Ahmad Al-Bitar, Fatima Al-Jojo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19042

e19042 Background: The ongoing conflict in Syria has significantly disrupted cancer surveillance, leading to a critical la...

Cancer-related overall survival for patients on durvalumab for stage III unresectable non–small cell lung cancer with PD-L1 positive and negative tumors.

Zohra Nooruddin, Corbyn Gilmore, Amanda Moore et al. Jun 01, 2026 pp. 8026-8026 10.1200/jco.2026.44.16_suppl.8026

8026 Background: Durvalumab improves overall survival (OS) and progression free survival (PFS) when used as consolidation...

A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in <i>IDH1</i> -mutated acute myeloid leukemia (AML).

Jennifer Marvin-Peek, Jacqueline Suen Garcia, Gautam Borthakur et al. Jun 01, 2026 pp. 6503-6503 10.1200/jco.2026.44.16_suppl.6503

6503 Background: Outcomes for patients with IDH1 mut AML have...

Phase II study of ceralasertib (ATR inhibitor) plus durvalumab in patients with advanced gastric cancer (AGC) who progressed on prior anti-PD-(L)1 therapy.

Sung Hee Lim, Minae An, Ji Eun Shin et al. Jun 01, 2026 pp. 4062-4062 10.1200/jco.2026.44.16_suppl.4062

4062 Background: The standard first-line therapy for advanced gastric cancer (AGC) now includes immune checkpoint inhibito...

Importance of where you die: Lung cancer mortality trends in homeless-proxy settings across the U.S.

Besseri Emmanuel Christian Ako, Eric Wah Sanji, Fomengia Joseph Nkeangu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13755

e13755 Background: Homelessness significantly impacts health, contributing to worse cancer outcomes and higher death rates...

Glucagon-like peptide-1 injectable medication uptake among United States cancer survivors with diabetes: National estimates and socioeconomic patterns from 2024.

Aditya Pandey, Jay Tewari, Vanshika Singh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23094

e23094 Background: Use of glucagon-like peptide-1 (GLP-1) receptor agonists has expanded rapidly for diabetes and obesity...

Neoadjuvant apatinib plus camrelizumab in renal cell carcinoma with inferior vena cava tumor thrombus: Results of a phase II study.

Ruiyang Xie, Ye Yan, Liyuan Ge et al. Jun 01, 2026 pp. 4536-4536 10.1200/jco.2026.44.16_suppl.4536

4536 Background: Renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVCTT) remains a surgically challengin...

Demographic and socioeconomic patterns of malignant melanoma in junctional nevus: An NCDB analysis.

Elizabeth Hammer, Eugene Manu, Amber Chang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21572

e21572 Background: Malignant melanoma in junctional nevus (MMJN) is a rare type of cutaneous melanoma that originates in m...

Real-world efficacy and safety of photoimmunotherapy for recurrent nasopharyngeal carcinoma: A nationwide multicenter study in Japan.

Hideki Tanaka, Takeshi Shinozaki, Takao Fujisawa et al. Jun 01, 2026 pp. 6030-6030 10.1200/jco.2026.44.16_suppl.6030

6030 Background: Treatment options for locally recurrent or residual nasopharyngeal carcinoma (NPC) after definitive radio...

IL7-IL15 fusion cytokine (fusokine)–secreting iPSC-derived mesenchymal stromal cells to convert immunosuppressive into highly immune-activated tumor microenvironments (TMEs), potentiate antitumor immunity, and synergize with PD-1 inhibition in ovarian cancer.

Michael Andreeff, Sandeep Singh, Andrea D. Bedoy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14522

e14522 Background: Mesenchymal stromal cells (MSCs) exhibit inherent tumor-homing properties and can be programmed to prod...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page